Immunotherapy and Immune Checkpoints

Antibody therapies are the most successful immunotherapy, treating a wide range of cancers. Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. In normal physiology the immune system uses them to fight pathogens. Each antibody is specific to one or a few proteins. Those that bind to cancer antigens are used to treat cancer. Cell surface receptors are common targets for antibody therapies. Among the most promising approaches to activating therapeutic antitumor immunity is the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. It is now clear that tumors co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumor antigens. Because many of the immune checkpoints are initiated by ligand–receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunetherapeutics to achieve US Food and Drug Administration (FDA) approval.

  • Combinations of Check-Point Inhibitors
  • In Vivo Discovery of Immunotherapy Targets
  • Immune Suppression and Microenvironment
  • Sequencing or Combination Approaches in Immunotherapy
  • Chimeric Antigen Receptor Re-Directed T Cell Therapy

Related Conference of Immunotherapy and Immune Checkpoints

April 04-05, 2024

38th International Conference on Immunology

Madrid, Spain
May 23-24, 2024

18th International Conference on European Immunology

Zurich, Switzerland

Immunotherapy and Immune Checkpoints Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in